Matches in SemOpenAlex for { <https://semopenalex.org/work/W2972162730> ?p ?o ?g. }
Showing items 1 to 94 of
94
with 100 items per page.
- W2972162730 endingPage "iii5" @default.
- W2972162730 startingPage "iii4" @default.
- W2972162730 abstract "Abstract BACKGROUND Given the mechanism of action of immune checkpoint inhibitors (ICIs), a possible association with the development of paraneoplastic neurological syndromes (PNS) has been hypothesized. We sought to determine if ICI treatment might trigger anti-Ma2 antibody-associated paraneoplastic neurological syndromes (Ma2-PNS). MATERIAL AND METHODS We performed a retrospective nationwide study of all patients with Ma2-PNS developed during ICI treatment between 2017–2018. The frequency of neuronal-antibody detection before and after ICI implementation was also analyzed. RESULTS Our series of patients included 5 men and 1 woman (median age, 63 years). The patients were receiving either nivolumab (n = 3), pembrolizumab (n = 2) or a combination of nivolumab and ipilimumab (n=1), for treatment of neoplasms that included lung (n=4) and kidney (n=1) cancers, and pleural mesothelioma (n=1). Median delay between ICI introduction and onset of the neurological syndrome was 4 months. Clinical syndromes included a combination of limbic encephalitis and diencephalitis (n=3), isolated limbic encephalitis (n=2) and a syndrome characterized by opthalmoplegia and head-drop (n=1). Patients with diencephalitis manifested hyperphagia, weight gain and somnolence. Post-ICI Ma2-PNS accounted for 35% of the total 17 Ma2-PNS diagnosed in our center over the 2017–2018 biennium. Eight cases had been detected in the preceding biennium 2015–2016, corresponding to a 112% increase of Ma2-PNS frequency since the implementation of ICIs in France. No other neuronal-antibody demonstrated a similar increment. CONCLUSION We show a clear association between ICI use and increased frequency of Ma2-PNS. Physicians need to be aware that ICIs can trigger Ma2-PNS since clinical presentation can be challenging." @default.
- W2972162730 created "2019-09-12" @default.
- W2972162730 creator A5009156284 @default.
- W2972162730 creator A5018945796 @default.
- W2972162730 creator A5023410585 @default.
- W2972162730 creator A5027817628 @default.
- W2972162730 creator A5029282520 @default.
- W2972162730 creator A5036402982 @default.
- W2972162730 creator A5041210426 @default.
- W2972162730 creator A5048569749 @default.
- W2972162730 creator A5055824130 @default.
- W2972162730 creator A5059859090 @default.
- W2972162730 creator A5059937656 @default.
- W2972162730 creator A5061141183 @default.
- W2972162730 creator A5063198158 @default.
- W2972162730 creator A5071502431 @default.
- W2972162730 creator A5071650409 @default.
- W2972162730 creator A5078362705 @default.
- W2972162730 creator A5081340987 @default.
- W2972162730 date "2019-08-01" @default.
- W2972162730 modified "2023-10-01" @default.
- W2972162730 title "JS1.2 Increased frequency of paraneoplastic encephalitis with anti-Ma2 antibodies in the cancer immunotherapy era" @default.
- W2972162730 doi "https://doi.org/10.1093/neuonc/noz126.011" @default.
- W2972162730 hasPublicationYear "2019" @default.
- W2972162730 type Work @default.
- W2972162730 sameAs 2972162730 @default.
- W2972162730 citedByCount "0" @default.
- W2972162730 crossrefType "journal-article" @default.
- W2972162730 hasAuthorship W2972162730A5009156284 @default.
- W2972162730 hasAuthorship W2972162730A5018945796 @default.
- W2972162730 hasAuthorship W2972162730A5023410585 @default.
- W2972162730 hasAuthorship W2972162730A5027817628 @default.
- W2972162730 hasAuthorship W2972162730A5029282520 @default.
- W2972162730 hasAuthorship W2972162730A5036402982 @default.
- W2972162730 hasAuthorship W2972162730A5041210426 @default.
- W2972162730 hasAuthorship W2972162730A5048569749 @default.
- W2972162730 hasAuthorship W2972162730A5055824130 @default.
- W2972162730 hasAuthorship W2972162730A5059859090 @default.
- W2972162730 hasAuthorship W2972162730A5059937656 @default.
- W2972162730 hasAuthorship W2972162730A5061141183 @default.
- W2972162730 hasAuthorship W2972162730A5063198158 @default.
- W2972162730 hasAuthorship W2972162730A5071502431 @default.
- W2972162730 hasAuthorship W2972162730A5071650409 @default.
- W2972162730 hasAuthorship W2972162730A5078362705 @default.
- W2972162730 hasAuthorship W2972162730A5081340987 @default.
- W2972162730 hasBestOaLocation W29721627301 @default.
- W2972162730 hasConcept C121608353 @default.
- W2972162730 hasConcept C126322002 @default.
- W2972162730 hasConcept C159654299 @default.
- W2972162730 hasConcept C163764329 @default.
- W2972162730 hasConcept C203014093 @default.
- W2972162730 hasConcept C2776256026 @default.
- W2972162730 hasConcept C2777699746 @default.
- W2972162730 hasConcept C2777701055 @default.
- W2972162730 hasConcept C2780030458 @default.
- W2972162730 hasConcept C2780057760 @default.
- W2972162730 hasConcept C2781433595 @default.
- W2972162730 hasConcept C71924100 @default.
- W2972162730 hasConcept C90924648 @default.
- W2972162730 hasConceptScore W2972162730C121608353 @default.
- W2972162730 hasConceptScore W2972162730C126322002 @default.
- W2972162730 hasConceptScore W2972162730C159654299 @default.
- W2972162730 hasConceptScore W2972162730C163764329 @default.
- W2972162730 hasConceptScore W2972162730C203014093 @default.
- W2972162730 hasConceptScore W2972162730C2776256026 @default.
- W2972162730 hasConceptScore W2972162730C2777699746 @default.
- W2972162730 hasConceptScore W2972162730C2777701055 @default.
- W2972162730 hasConceptScore W2972162730C2780030458 @default.
- W2972162730 hasConceptScore W2972162730C2780057760 @default.
- W2972162730 hasConceptScore W2972162730C2781433595 @default.
- W2972162730 hasConceptScore W2972162730C71924100 @default.
- W2972162730 hasConceptScore W2972162730C90924648 @default.
- W2972162730 hasIssue "Supplement_3" @default.
- W2972162730 hasLocation W29721627301 @default.
- W2972162730 hasLocation W29721627302 @default.
- W2972162730 hasOpenAccess W2972162730 @default.
- W2972162730 hasPrimaryLocation W29721627301 @default.
- W2972162730 hasRelatedWork W2091729697 @default.
- W2972162730 hasRelatedWork W2269603252 @default.
- W2972162730 hasRelatedWork W2285109017 @default.
- W2972162730 hasRelatedWork W2592882046 @default.
- W2972162730 hasRelatedWork W2767114511 @default.
- W2972162730 hasRelatedWork W2780004360 @default.
- W2972162730 hasRelatedWork W3021504039 @default.
- W2972162730 hasRelatedWork W3029766637 @default.
- W2972162730 hasRelatedWork W3215044659 @default.
- W2972162730 hasRelatedWork W4292999071 @default.
- W2972162730 hasVolume "21" @default.
- W2972162730 isParatext "false" @default.
- W2972162730 isRetracted "false" @default.
- W2972162730 magId "2972162730" @default.
- W2972162730 workType "article" @default.